Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × prednylidene × Genitourinary × Clear all

Phase

Status

Active not recruiting 7 Recruiting 5 Terminated 4 Completed 4 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 15 Prednisone 13 Docetaxel 13 Magnetic Resonance Spectroscopy 12 Radiotherapy 10 bicalutamide 9 Leuprolide 8 Cyclophosphamide 8 Biopsy 8 avelumab 7 Radiosurgery 7 Abiraterone Acetate 7 atezolizumab 6 Specimen Handling 6 Interleukin-2 6 gallium 68 PSMA-11 5 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 Paclitaxel 5 Metformin 5 Gemcitabine 5 Bevacizumab 5 Androgen Antagonists 5 enzalutamide 4 apalutamide 4 Sunitinib 4 Sorafenib 4 Radiation 4 Injections 4 Goserelin 4 Cisplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00598858 2016-12-08

2007-5904

University of California, Irvine

Phase 2 Withdrawn

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡